What are the side effects of levacetylleucine?

Levacetylleucine . As the first modified amino acid drug approved to treat neurological symptoms of Niemann-Pick disease type C (NPC; a rare disease), its safety profile has been initially evaluated in clinical trials and real-world applications. This rare disease treatment drug not only improves core symptoms of patients such as ataxia and cognitive dysfunction, but also exhibits a specific spectrum of adverse reactions.

Clinical study data show that the most common adverse reactions include upper respiratory tract infection, abdominal pain, dysphagia and vomiting. These symptoms are mostly mild to moderate and usually do not require interruption of treatment. It is worth noting that the preparation and administration of the drug may affect tolerance. There are special requirements for mixing levoacetylleucine granules with 40ml of cold water or a specific liquid and then taking it within 30 minutes. Improper operation may aggravate gastrointestinal discomfort.

Of particular concern is the drug's clear embryo-fetal toxicity warning. Animal experiments show that exposures equivalent to 1.4-6 times the recommended human dose can cause serious developmental abnormalities such as embryonic death and skeletal deformities. This discovery requires women of childbearing age to confirm that they are not pregnant before taking the drug, and to take effective contraceptive measures during the entire treatment period and within 7 days after stopping the drug. Those with unwanted pregnancies should stop taking the drug immediately and receive professional prenatal consultation

In the application of special populations, although the drug is approved for use in children 4 years old and above, the safety data of the drug in children under 15kg are still limited, and growth and development indicators need to be closely monitored.

Overall, the benefit-risk ratio of levoacetylleucine is of positive significance for NPC patients under the premise of strict compliance with medication guidelines, but a complete medication monitoring system needs to be established to ensure treatment safety.

Reference materials:https://en.wikipedia.org/wiki/Levacetylleucine